Pre-made Zansecimab benchmark antibody ( Whole mAb, anti-ANGPT2 therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-641

Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Zansecimab (formerly LY 3127804) is a selective monoclonal antibody against angiopoietin 2 (Ang2), being developed by Eli Lilly and Company, for the treatment of solid tumours including gastric cancer and hepatocellular carcinoma (HCC) and COVID-19 pneumonia.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-641-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody
INN Name Zansecimab
TargetANGPT2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesEli Lilly
Conditions Approvedna
Conditions ActiveCOVID-19
Conditions DiscontinuedSolid tumours
Development Techna